Elixir
NAD+ learning · Published by Elixir

How to read NAD research

Identify the exact substance, route, participants and measured outcome before deciding what a NAD-related study supports.

15 October 20262 min readUK adults 18+
Open research papers, a notebook and reading glasses.
AI-generated editorial image.

Start with the study, then the claim

  1. Population: who was studied? Record the health context and numbers enrolled and completing.
  2. Design: laboratory, animal, observational or human intervention? Was there a comparator and random allocation?
  3. Intervention: record the exact ingredient, formulation and route.
  4. Outcome: distinguish a laboratory marker from an outcome people experience.
  5. Time: a short trial cannot establish effects over years.
  6. Limitations: note missing data, uncertainty, exclusions, funding and conflicts.

A worked reading example

Martens and colleagues studied oral NR in healthy adults aged 55–79. Thirty people were randomised and 24 completed a double-blind, placebo-controlled crossover trial with two six-week periods. There was no formal washout; the authors checked for carryover and reported none. The physiological observations required larger trials. NIH grants supported the work; ChromaDex supplied study pills, analytical standards and partial funding. The authors declared no competing interests.

This study does not establish longer life, benefits for everyone or the effect of a different marketed product. It is a reading example, not a recommendation to take NR.

Compare without combining unlike studies

A small NMN trial in postmenopausal women with prediabetes and an IV NAD+ metabolism pilot in men cannot be pooled informally into a promise about all NAD products. See the focused study ledger for their different designs and limits.

Useful terms

Randomised
Participants are allocated by chance.
Placebo
A comparison designed to resemble the intervention.
Crossover
Participants receive different conditions in successive periods.
Washout and carryover
A washout is a gap between periods; carryover is a remaining effect from an earlier condition.
Biomarker
A measured biological feature, not automatic evidence of a meaningful health benefit.

Make a claim-to-source note

Write the claim in one column, the exact paper in another, and what that paper can and cannot establish in a third. A mismatch in route, ingredient, population or outcome is a reason to narrow the statement. A citation does not remove that mismatch.

Sources and scope

Sources checked 15 October 2026. This is a focused educational resource, not a systematic review or evidence that an Elixir product has a health benefit. No clinician review is claimed.